Эпикур

Selected form

Lansoprazol

Treatment option: Gastroesophageal Reflux Disease, Duodenal Ulcer, Reflux, Zollinger-Ellison Syndrome, Helicobacter Pylori, Stomach Ulcer

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Эпикур

Property	Description
Active ingredient	Lansoprazol (Lansoprazole)
Form	Delayed-release capsule or tablet
Pharmacological class	Proton Pump Inhibitor (PPI)
Common purpose	Sustained reduction of stomach acid
Origin	Synthetic chemical compound

Эпикур: What Type of Medicine is Lansoprazol?

Эпикур is the commercial designation for a synthetic pharmaceutical product containing the active substance Lansoprazol, which is firmly categorized as a Proton Pump Inhibitor (PPI). Lansoprazol is structurally identified as a substituted benzimidazole derivative. This classification confirms its role as a potent antisecretory agent designed for the high-level, persistent control of gastric acidity, a capability for achieving superior acid suppression compared to older H2-blocker therapies.

Composition and Form: Why is Эпикур a Delayed-Release Capsule?

The medication is formulated for oral administration and is typically presented as a delayed-release capsule. The composition requires that the active ingredient, Lansoprazol, be protected by an enteric coating, which is crucial because the drug is highly sensitive to degradation by stomach acid. This structural necessity is a differentiating factor within the PPI class: since Lansoprazol is one of the more acid-labile compounds, its protected formulation ensures delivery of the dose. This system guarantees the substance remains intact until it reaches the less-acidic small intestine, ensuring its proper absorption.

General Purpose: How Lansoprazol Reduces Stomach Acidity

The primary general purpose of Lansoprazol is to achieve profound and sustained suppression of gastric acid secretion. It functions by directly targeting and blocking the H^+K^+-ATPase enzyme system—the Proton Pump—which is the final step responsible for releasing acid into the stomach. This highly specific action provides the therapeutic benefit of consistently lowering the overall acidity level, thereby reducing the discomfort associated with acid excess and promoting favorable conditions for digestive tissue protection.

What side effects are possible with Эпикур?

Possible Side Effects and Safety Information: Эпикур

This safety information reflects the structured adverse reaction data typically documented in authoritative governmental regulatory sources (such as the EMA/ICH framework).

Adverse Reaction Categories

Regulatory documents organize adverse reactions by frequency and the System-Organ Class (SOC) affected. The most frequently reported adverse effects are categorized as Very Common or Common and typically involve the gastrointestinal system or flu-like syndromes.

Classification	Examples of Adverse Reactions (by System-Organ Class)
Very Common	Gastrointestinal disorders (e.g., Nausea, Vomiting).
Common	Vascular disorders (e.g., Hypertension), Infections (e.g., Febrile Neutropenia).
Rare	Respiratory, Thoracic, and Mediastinal disorders (e.g., Interstitial Pneumonia, Pulmonary Oedema).

Serious Adverse Reactions

The official safety profile highlights several serious adverse reactions, which, while categorized as Rare, represent Important Identified Risks that require specific regulatory attention. These include potentially fatal events such as severe cerebral oedema and serious respiratory complications like interstitial pneumonia and pulmonary embolism.

Other serious events documented in regulatory sources include Thrombocytopenia (a blood disorder) and Tumour Haemorrhage.

Safety Considerations and Limitations

Time-Related Patterns: Flu-like symptoms are noted to be most prominent at the initiation of therapy and tend to decrease in frequency with continued exposure.
Population-Specific Notes: Safety documents may note an increased risk of serious pulmonary events in patients with a recent history of pulmonary infiltrates or pneumonia.
Safety Restrictions: Specific signs—such as new onset of cough, fever, and dyspnoea—are formally documented as being preliminary signs for serious conditions like Adult Respiratory Distress Syndrome (ARDS), which are associated with this type of drug class and necessitate careful regulatory monitoring. The primary structure of the regulatory safety profile is to provide a clear, categorized view of both expected and rare, serious risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of any prescription medication, including Эпикур, is a medical emergency that requires immediate professional attention. The risk of a serious or fatal outcome increases with higher doses, taking medication that was not prescribed to you, or combining it with other substances that affect the central nervous system, such as alcohol or sedatives (like benzodiazepines).

Signs of an overdose typically involve depression of the central nervous system and respiration. These critical manifestations may include:

Respiratory Distress: Slow, shallow, or stopped breathing.
Consciousness Changes: Extreme drowsiness, inability to wake up, or coma.
Physical Signs: Limp body, cold and clammy skin, discolored skin (especially blue/grey lips or nails), and very small or pinpoint pupils.

Required Emergency Actions

If an overdose is suspected, call emergency services immediately (such as 911 or your local emergency number). This action is required even if the person wakes up or begins to feel better. If available, administer an opioid overdose reversal medication, such as naloxone, if trained to do so. Lay the person on their side to prevent choking if vomiting occurs and remain with them until emergency responders arrive.

Therapeutic Uses of Эпикур

The drug Эпикур (Epirubicin) belongs to the anthracycline class of chemotherapeutic agents, a group of compounds commonly used across conditions presenting with acute episodes of malignant cell proliferation. The core therapeutic domain for this class plays a role in the management of various cancers, including various types of malignancies and tumors.

Specifically, this medication is commonly used to help with conditions involving episodic or fluctuating manifestations of cancer, such as solid tumors like breast cancer and certain blood cancers like leukemias. In clinical settings that involve acute or unstable symptom patterns, therapy with Epirubicin supports the overall management plan. “It is considered relevant for easing the overall systemic burden caused by rapidly dividing cells.” It may provide supportive relief that helps ease the overall symptom burden and may assist with general well-being during symptomatic phases.

Quick Fact: Supports relief for symptoms related to heightened physiological activity.

Regulatory References

NIH StatPearls overview of Anthracycline Medications

Eligibility and Restrictions for Use

The eligibility for Эпикур (Lansoprazole) is strictly defined by government regulatory agencies through clear inclusion and exclusion criteria.

Eligibility Scope

The medicine is contraindicated in patients with a documented hypersensitivity to Lansoprazole, substituted benzimidazoles, or any excipients in the formulation. Co-administration is explicitly prohibited with certain antiviral medications, including rilpivirine and atazanavir.

Age and Developmental Status

Use is not recommended in infants under one year of age, as safety and efficacy have not been established in this developmental stage. The drug is otherwise established for use in adults and in pediatric patients aged 1 to 17 years for specific, labeled conditions. Older adults are subject to a maximum daily dose constraint unless compelling clinical reasons warrant otherwise.

Conditional and Restricted Use

Patients with moderate or severe hepatic dysfunction are restricted and require close supervision. Use is not recommended during pregnancy and lactation due to limited human data, establishing a restrictive eligibility status in these populations. Conditional use is also required for patients with suspected gastric malignancy, which must be formally ruled out prior to ongoing administration. Additionally, some formulations are contraindicated for patients with specific hereditary sugar intolerances.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents highlight two primary domains governing the interaction profile of Epirubicin: pharmacokinetic exposure modification and additive toxicity risk.

Contraindicated Combinations

Co-administration with live or live-attenuated vaccines is formally contraindicated due to the immunosuppressive effect of Epirubicin, which creates a risk of serious or fatal infection [Source: FDA Prescribing Information].

Exposure-Modifying Interactions (Pharmacokinetic)

One substance is specifically documented in regulatory labeling for altering Epirubicin exposure:

Cimetidine: Co-administration with this H2-receptor antagonist is confirmed to significantly increase Epirubicin's systemic exposure (AUC by 50% and plasma clearance reduced by 30%). This requires that Cimetidine treatment must be stopped during Epirubicin therapy [Source: FDA Prescribing Information].

Pharmacodynamic Toxicity Risks

Interactions in this category increase the overall risk of organ damage or system suppression:

Interacting Product Category	Official Interaction Description
Cardiotoxic Drugs (e.g., Trastuzumab)	Concomitant use increases the risk of cardiac toxicity, as effects are additive. Administration of Epirubicin should be delayed until long half-life agents clear circulation.
Myelosuppressive Agents	Combination with other cytotoxic drugs or DNA-damaging agents potentiates myelosuppressive toxicity [Source: EMA SmPC].
Radiation Therapy	Prior or concomitant radiotherapy to the mediastinal/pericardial area increases the risk of cardiac toxicity [Source: FDA Prescribing Information].

Population-Specific Interaction Notes

Patients with impaired hepatic function have a reduction in Epirubicin clearance, which is an interaction consideration that increases overall toxicity and mandates dosage reduction according to label-defined bilirubin levels [Source: EMA SmPC].

Mechanism of Action

Эпикур is a selective, high-affinity antagonist of the RANKL/RANK signaling axis. The drug is designed to bind to RANKL (Receptor Activator of Nuclear Factor κB Ligand), preventing its interaction with its cognate receptor, RANK, which is expressed on the surface of pre-osteoclasts and mature osteoclasts. This blockade results in the inhibition of RANKL-mediated signaling, which is critical for osteoclast differentiation, function, and survival. Consequently, the downstream cascade of intracellular signaling is interrupted, leading to a marked reduction in the activity and formation of bone-resorbing osteoclasts. The resulting physiological modulation is a decrease in the overall rate of bone turnover and a shift in the local bone remodeling unit balance toward net bone accumulation.

Dosage and Administration Information

How to use Эпикур — Administration Guidelines

Treatment with this medication (sofosbuvir/velpatasvir) is administered orally and typically follows a 12-week course for adults, regardless of whether it is an oral tablet or oral pellets.

Dosing and Administration

Patient Population	Daily Dose (Oral)	Timing/Duration
Adults (without cirrhosis or with compensated cirrhosis)	One 400 mg/100 mg tablet	Once daily for 12 weeks
Adults (with decompensated cirrhosis)	One 400 mg/100 mg tablet plus ribavirin	Once daily for 12 weeks

Route of Administration: The tablet must be swallowed whole and should not be crushed or chewed. It may be taken with or without food.

Pediatric Use: For patients 3 years of age and older, the recommended dosage is determined by body weight and may be administered as a tablet or oral pellets. Specifically, in pediatric patients less than 6 years of age, the oral pellets must be administered with food to enhance tolerability. When using oral pellets, they can be sprinkled onto a small amount of non-acidic soft food (like pudding or ice cream) and the entire mixture should be consumed within 15 minutes without chewing the pellets.

Procedural Steps and Missed Doses

Prior to starting treatment, all patients must be tested for evidence of current or prior Hepatitis B Virus (HBV) infection. If a scheduled dose is missed, it should be taken as soon as possible, unless it is almost time for the next dose. In that case, the missed dose must be skipped, and the regular dosing schedule resumed; do not take a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Intended Action and Study Focus

Research has explored the drug's intended biological pathway in chronic arthritis. Studies evaluated whether the drug's use was associated with changes in patient-reported pain levels and inflammation markers.

Phase III Clinical Trials
- Two key trials evaluated changes in specific measures of joint function and patient-assessed stiffness in participants with moderate-to-severe arthritis over a 12-week period. These findings were compared to placebo groups.
- A smaller, single-center study examined the drug’s use when co-administered with a standard disease-modifying anti-rheumatic drug (DMARD).
- The combination approach was evaluated for its effect on disease activity scores, which demonstrated mixed results across different patient groups.

Long-Term Monitoring

Long-term studies (up to 52 weeks) documented adverse event profiles. The most common adverse events reported in these studies included headache, mild fatigue, and minor upper respiratory tract infections.

Gastrointestinal Effects
- Participants reported mild gastrointestinal side effects (such as nausea and indigestion).

Summary of Findings

In summary, studies examined whether the drug's use is associated with measured changes in inflammation markers and quality of life compared to control/placebo. Preliminary data included comparisons to standard therapies, but evidence remains limited regarding comparative long-term outcomes. These data contribute to the body of evidence that informs treatment decisions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Эпикур (FAQ)

Q: How long does the effect of Эпикур usually last?

The official product information indicates that the acid-blocking effect of Эпикур lasts for more than 24 hours. This sustained action occurs even though the drug itself has a short presence in the blood (a quick half-life), providing continuous acid control.

Q: Is it normal to feel a bit tired after taking Эпикур?

According to official regulatory documents, tiredness or fatigue is listed as a common side effect. This means it is one of the more frequently reported adverse reactions recorded during clinical trials and post-market surveillance. The experience of side effects may vary among individuals.

Q: Is Эпикур considered safe for older adults (seniors)?

Official regulatory documents confirm that dose accumulation is not generally expected when Эпикур is taken once daily, even though the body's process for clearing the medicine may be slower in older adults. Regulatory documentation notes that the overall health status of the elderly population may be a consideration in clinical settings, and clearance differences are documented.

Q: Is the mechanism of action of Эпикур fully understood by scientists?

The mechanism of action is clearly defined in official regulatory documents. It functions by inhibiting the Proton Pump ( H^+/ K^+ ATPase), which is the final step in the production of stomach acid by the body. This specific action allows the drug to consistently reduce overall gastric acidity.

Q: Is it true that Эпикур is only available by prescription?

No, Эпикур (Lansoprazole) is available in both formats, depending on its approved use. It is sold as an Over-the-Counter (OTC) product for treating common heartburn, and as a Prescription Drug when prescribed for more serious conditions like ulcers or severe reflux disease.

Q: Why do doctors prescribe Эпикур for multiple different conditions?

Эпикур is approved to treat several distinct problems related to excess stomach acid. Official labeling includes multiple approved indications, such as treating H. pylori infections, healing duodenal and gastric ulcers, and managing GERD (Gastroesophageal Reflux Disease) and Zollinger-Ellison Syndrome.

Q: What is the risk of an allergic reaction to Эпикур?

Official regulatory warnings highlight that signs of hypersensitivity or severe skin reactions (known as SCARs) have been reported. Due to this risk, the medicine is formally contraindicated in patients with a documented hypersensitivity to Lansoprazole or similar compounds.

Q: Can Эпикур affect my sleep or make me restless?

Official product documentation indicates that some effects on the nervous system have been listed among the less common side effects reported post-marketing. These include reports of insomnia (trouble sleeping) and anxiety or nervousness.

Q: Do any official documents describe Эпикур as being 'for' a chronic condition?

Yes, the official documentation lists Эпикур as being indicated for long-term use in Pathological Hypersecretory Conditions. This category includes the rare, chronic disorder known as **Zollinger-Ellison Syndrome ( ZES).

How should Эпикур be stored and disposed of?

How to Store and Dispose of Эпикур (Epirubicin Hydrochloride)

Official regulatory documents mandate strict storage and disposal requirements for Эпикур due to its nature as a cytotoxic agent.

Storage Conditions	In-Use Stability and Handling	Disposal Instructions
Intact vials must be refrigerated at 2 C to 8 C.	Solutions must be used immediately or stored for a limited time (e.g., 24 hours at 2 C to 8 C).	Unused product must be disposed of according to local requirements for antineoplastic agents.
Keep vials in the outer carton to protect from light.	Protect from freezing.	Do not dispose of product or waste in household trash or wastewater.
Store out of the sight and reach of children.	Handling must be performed by trained personnel.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Russia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z